Immune cell profile changes in patients treated with tarlatamab for extensive stage small cell lung cancer in real world practice
Presenter: Dhauna Karam Prasad, MD;PhD Session: Prognostic Biomarkers 2 Time: 4/20/2026 2:00:00 PM → 4/20/2026 5:00:00 PM
Authors
Dhauna Karam Prasad 1 , Andre De Menezes Silva Corraes 1 , Malvika Gupta 1 , Audrey Ma 2 , Chen Wu 1 , Zuoyi Shao 1 , Kevin Reagan 1 , Rayaan Kamal 1 , Ashley Potter 1 , Abdullah Al-Ajmi 1 , Syeda Mina 1 , Sykler J. Taylor 1 , Antonious Hazim 1 , Anastasios Dimou 1 , Kaushal Parikh 1 , Mohammed Shanshal 1 , Ailsa Luce 1 , Anna Schwecke 1 , Julian Molina 1 , Aaron Mansfield 1 , Katherine Smith 1 , Lucy Holmes 1 , Haidong Dong 1 , Yi Lin 1 , Konstantinos Leventakos 1 1 Mayo Clinic Cancer Center Minnesota, Rochester, MN, 2 Columbia University, New York, NY
Abstract
Background: Tarlatamab, a Delta-like ligand (DLL3)/CD3-targeted bispecific T-cell engager (TCE) is FDA approved in patients (pts) with extensive stage small cell lung cancer (ES-SCLC), after progression on frontline chemoimmunotherapy. We aimed to evaluate the immune cell profile in pts who received this therapy in standard-of-care (SOC) practice with progression free survival (PFS) less than and greater than two months (mo). Methods: Patients who received tarlatamab at Mayo Clinic Rochester and consented to immuno phenotyping of blood are included in the present study. Immune phenotyping was performed on whole blood by flow cytometry and analyzed by Kaluza. Data analysis was performed with Microsoft Excel and PRISM. Results: Eighteen patients with median age 64 (range 37-79) were included in the study. 66% of our cohort were women and 83% had present or past history of smoking, with an average of 40 pack years (range 26-60). With a median follow-up of 2 months, the median PFS for the cohort was 1.5 mo (range 0.33-2.76 months). 61% (13/18) of patients had PFS 2mo and of which, three patients had partial response with one maintaining stable disease and one patient with mixed response. At baseline (BL), there were no difference in T cell, CD4 or CD8 cell count between patients in the PFS 2mo groups. Patients with PFS 2mo group (CD8+PD1+TIGIT+CD57+, PFS 3mo, cells/mL: 7.14±4.28, 1.58±1.37, p=0.009). Additionally, when analyzing the B-cell population, the PFS 2mo at baseline (6.0±7.5, 10.4±14, p=0.02). At day 7, the group with PFS 2mo (2.88±1.38, 4.60±1.47, p=0.02). Also, the PFS 2mo at day 7( 2mo: 10.0±14, 4.37±3.07, p=0.04). Finally, the group with PFS>2mo had decrease in total monocytes (mono), classical mono, and immunosuppressive cells (PFS 2mo, Mono: 340±347, 253±106, p=0.04. Classical mono: 305±283, 155±109, p=0.02. CD14+HLA-DRneg: 105.8±96, 12±39, p=0.03) compared to the group with PFS 2mo group had decreased post treatment intermediate monocytes (BL vs day 7, cells/mL, intermed mono: 32.5±15,17.7±6.2, p=0.03). Conclusion: In this study investigating the SOC outcomes of tarlatamab, early progression was associated with higher presence of exhausted CD8 T cells, B cells, and immunosuppressive monocytes. Analysis of additional patients will be shared at AACR meeting.
Disclosure
D. Karam Prasad, None.. A. De Menezes Silva Corraes, None.. M. Gupta, None.. A. Ma, None.. C. Wu, None.. Z. Shao, None.. K. Reagan, None.. R. Kamal, None.. A. Potter, None.. A. Al-Ajmi, None.. S. Mina, None.. S. J. Taylor, None.. A. Hazim, None.. A. Dimou, None.. K. Parikh, None.. M. Shanshal, None.. A. Luce, None.. A. Schwecke, None.. J. Molina, None.. A. Mansfield, None.. K. Smith, None.. L. Holmes, None.. H. Dong, None. Y. Lin, Janssen, Sanofi, BMS, Regeneron, Genentech, Tessera, Legend, NexT Therapeutics Other, Advisory Board. Janssen, Kite/Gilead Other, Steering Committee. Janssen, BMS ). NexImmune, Caribou Other, Scientific Advisory Board. Pfizer Other, Data safety monitoring board. K. Leventakos, None.
Cited in
Control: 7676 · Presentation Id: 10107 · Meeting 21436